Pulsed administration for physiological estrogen replacement in mice

F1000Res. 2021 Aug 16:10:809. doi: 10.12688/f1000research.54501.1. eCollection 2021.

Abstract

Estrogens are important regulators of body physiology and have major effects on metabolism, bone, the immune- and central nervous systems. The specific mechanisms underlying the effects of estrogens on various cells, tissues and organs are unclear and mouse models constitute a powerful experimental tool to define the physiological and pathological properties of estrogens. Menopause can be mimicked in animal models by surgical removal of the ovaries and replacement therapy with 17β-estradiol in ovariectomized (OVX) mice is a common technique used to determine specific effects of the hormone. However, these studies are complicated by the non-monotonic dose-response of estradiol, when given as therapy. Increased knowledge of how to distribute estradiol in terms of solvent, dose, and administration frequency, is required in order to accurately mimic physiological conditions in studies where estradiol treatment is performed. In this study, mice were OVX and treated with physiological doses of 17β-estradiol-3-benzoate (E2) dissolved in miglyol or PBS. Subcutaneous injections were performed every 4 days to resemble the estrus cycle in mice. Results show that OVX induces an osteoporotic phenotype, fat accumulation and impairment of the locomotor ability, as expected. Pulsed administration of physiological doses of E2 dissolved in miglyol rescues the phenotypes induced by OVX. However, when E2 is dissolved in PBS the effects are less pronounced, possibly due to rapid wash out of the steroid.

Keywords: Estrogens; osteoporosis; ovariectomy; sex steroids; therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Central Nervous System
  • Estrogen Replacement Therapy*
  • Estrogens*
  • Female
  • Hormone Replacement Therapy
  • Humans
  • Mice
  • Ovariectomy

Substances

  • Estrogens

Grants and funding

This work was supported by grants from the Swedish Research Council (2016-01192 and 2020-01885, granted to UI), the Novo Nordisk Foundation (19928, granted to UI), the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-716421, granted to UI), the Marie Sklodowska Curie Action (833560 granted to CC and UI), the Association against Rheumatism (R-931683 and R-940384, granted to UI), King Gustav V’s 80 years’ foundation (FAI-2018-0573 and FAI-2020-0647, granted to UI), the Nanna Svartz foundation (2019-00281 and 2020-00338, granted to UI), the Emil and Wera Cornells foundation, the Åke Wiberg foundation (M20-0155, granted to CC), the Tore Nilsson foundation (2020-00799, granted to CC), and the IngaBritt and Arne Lundberg Foundation (LU-2018-0008 and LU2020-0010, granted to UI).